The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
513
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 1, 2012 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #306725 |
|
Title:
|
Predicting the Event Time in Multicenter Clinical Trials with Time-to-Event Outcome as Primary Endpoint
|
|
Author(s):
|
Nibedita Bandyopadhyay*+
|
|
Companies:
|
Janssen Pharmaceuticals R&D
|
|
Address:
|
920 Route 202 South, Raritan, NJ, 08869, United States
|
|
Keywords:
|
Interim analysis ;
multicenter clinical trials ;
prediction ;
survival analysis
|
|
Abstract:
|
Interim analyses are widely used in Phase II and III clinical trials. The efficiency in drug development process can be improved using interim analyses. In clinical trials with time to an event as primary endpoint, it is common to plan the interim analyses at pre-specified numbers of events. Performing these analyses at times with a different number of events than planned may impact the trial's credibility as well as the statistical properties of the interim analysis. On the other hand, significant resources are required in conducting such analyses. Therefore, for logistic planning purposes, it is very important to predict the timing of this pre-specified number of events early and accurately. A statistical technique for making such prediction in ongoing multicenter clinical trials is developed. Results are illustrated for different scenarios using simulations.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.